Trials / Completed
CompletedNCT00152425
Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).
A Phase III Multi-national, Multi-centre, Double-blind Placebo-controlled Parallel Group, 26 Week Study to Assess the Maintenance of Clinical Response to Humanised Anti-TNF PEG Conjugate, CDP870 400 mg sc, (Dosed 4-weekly From Weeks 8 to 24), in the Treatment of Patients With Active Crohn's Disease Who Have Responded to Open Induction Therapy (Dosed at Weeks 0, 2 and 4) With CDP870
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 392 (planned)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
A 26 week maintenance study of CDP870 in Crohn's disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Certolizumab Pegol (CDP870) |
Timeline
- Start date
- 2004-02-01
- Primary completion
- 2005-05-01
- Completion
- 2005-05-01
- First posted
- 2005-09-09
- Last updated
- 2013-09-09
Source: ClinicalTrials.gov record NCT00152425. Inclusion in this directory is not an endorsement.